Highest-materiality recent filing
DexCom sets 10%+ annual organic revenue growth target through 2030; authorizes $1B share buyback
Long-range target: organic revenue growth 10%+ every year through 2030.
Dexcom Q1 revenue $1.19B (+15% YoY), EPS $0.51; raises margin guidance
Q1 revenue $1.192B (+15% YoY); GAAP diluted EPS $0.51, non-GAAP $0.56.
Kevin Sayer returns as DexCom Executive Chairman on Mar 2 with new comp terms
Kevin Sayer returns from temporary leave effective March 2, 2026, resuming Executive Chairman role.
Dexcom Q4 revenue $1.26B (+13% YoY); GAAP EPS $0.68; FY2026 guidance $5.16-5.25B
GAAP operating income $323M (25.6% margin), up 860bps YoY; Non-GAAP op income $331.5M.
Dexcom Q4 revenue $1.26B beats high end; FY2026 outlook $5.16-5.25B; new CEO Jake Leach
Q4 total revenue ~$1.260B (+13% YoY), US $892M (+11%), Intl $368M (+18%).
DexCom appoints Jacob Leach as CEO effective Jan 1, 2026; sets compensation terms
Jacob S. Leach promoted to CEO from President/COO; effective Jan 1, 2026, succeeding Kevin Sayer on medical leave.
Dexcom Q3 revenue $1.209B (+22% YoY); raises FY 2025 revenue guidance to $4.63-4.65B
GAAP EPS $0.70 vs $0.34 YoY; non-GAAP EPS $0.61 vs $0.45 YoY.
DexCom CEO Kevin Sayer takes temporary medical leave; Jacob Leach appointed interim CEO
Kevin R. Sayer, CEO and Chairman, takes temporary medical leave effective Sept 14, 2025.
Revenue $1.157B (+15% YoY); GAAP EPS $0.45, non-GAAP EPS $0.48.
DexCom Q1 revenue $1.04B (+12% YoY); guides FY25 gross margin ~62% (down); announces $750M buyback
GAAP net income $105.4M ($0.27 diluted EPS) vs $146.4M ($0.36) YoY; non-GAAP EPS $0.32 flat.
DexCom receives FDA warning letter for manufacturing deficiencies; reaffirms FY2025 revenue guidance
FDA warning letter cites non-conformities in manufacturing processes and quality systems at San Diego and Mesa facilities.
Dexcom Q4 revenue $1.114B (+8% YoY); GAAP EPS $0.38; FY2025 guidance $4.6B
Q4 revenue $1.114B (+8% YoY); U.S. +4%, international +17% reported.
Dexcom reports preliminary Q4 revenue $1.113B (+8% YoY); guides 2025 revenue $4.60B (+14%)
Q4 2024 preliminary revenue at least $1.113B, up 8% YoY; US revenue $803M (+4%), international $310M (+17%).
DexCom and Abbott settle global patent litigation, enter royalty-free cross-license
DexCom and Abbott signed a settlement and patent cross-license agreement on Dec 20, 2024.
Dexcom Q3 revenue $994M (+2%); reiterates FY24 guidance; CCO retiring
Revenue $994.2M (+2% reported, +3% organic); U.S. down 2%, international up 12%.
Dexcom Q2 rev $1.004B (+15%); GAAP EPS $0.35; lowers FY rev guidance to $4.00-4.05B
Revenue $1.004B (+15% YoY); US +19%, intl +7% reported; organic growth 16%.
Dexcom Q1 revenue up 24% to $921M; GAAP EPS $0.36; updates FY guidance to $4.2-4.35B
Revenue $921M (+24% YoY); GAAP net income $146.4M ($0.36 EPS) vs $48.6M ($0.12) in Q1 2023.
DexCom terminates warrants for 10.3M shares with Bank of America
Termination agreement with BofA on Feb 13, 2024, stops warrants covering 10.3M shares of common stock.
Dexcom Q4 2023 revenue $1.03B, up 27%; GAAP EPS $0.62; FY2024 guidance $4.15-4.35B
Q4 2023 revenue $1.03B (+27% YoY); GAAP operating income $216.9M (21.0% margin).
DexCom reports preliminary Q4 revenue ≥$1.03B (+26% YoY); FY2024 guidance $4.15-4.35B
Preliminary Q4 2023 revenue at least $1.030B, up 26% YoY; FY2023 revenue ~$3.62B (+24%).
DexCom board authorizes $500M share repurchase program through Oct 2024
Board authorized up to $500M repurchase of outstanding common stock.
Dexcom Q3 revenue up 27% to $975M; raises FY2023 guidance, announces $500M buyback
GAAP revenue $975.0M (+27% YoY); U.S. +24%, international +33%.
Dexcom Q2 revenue $871.3M (+25% YoY), raises FY 2023 guidance
Revenue $871.3M (+25% YoY); GAAP EPS $0.28, non-GAAP EPS $0.34.
Dexcom raises 2025 revenue target to $4.6-5.1B, operating margin to 21%
2025 revenue target raised to ~$4.6-5.1B from prior $4.0-4.5B.
DexCom completes $1.25B convertible notes offering, buys back $188.7M of common stock
Issued $1.25B of 0.375% convertible senior notes due 2028, including full exercise of $150M additional note option.
DexCom prices upsized $1.1B 0.375% convertible notes due 2028; repurchases $188.7M of stock
Offering raised to $1.1B from initially announced $1.0B; initial purchasers have 13-day option for additional $150M.
Dexcom proposes $1.0B convertible notes due 2028; plans $250M share buyback
Offering $1.0B aggregate principal of Convertible Senior Notes due 2028, with option for up to $150M additional.
Dexcom Q1 revenue $741.5M (+18% YoY); raises FY 2023 guidance to $3.4-3.515B
Revenue $741.5M (+18% YoY, +19% organic); US +17%, Intl +21% reported (+27% organic).
Dexcom Q4 revenue $815.2M (+17% YoY); G7 CGM FDA cleared; guides 2023 rev $3.35-3.49B
Q4 2022 revenue $815.2M (+17% reported, +20% organic); U.S. +17%, international +15% (organic +27%).
Dexcom reports Q4 2022 preliminary revenue at least $815M (+17% YoY); FY2023 guidance $3.35-3.49B
Q4 2022 preliminary revenue at least $815M, up 17% YoY; U.S. $606M, international $209M.
Dexcom Q3 revenue $769.6M (+18% YoY); non-GAAP EPS $0.28; guides FY22 ~$2.88-2.91B
Revenue $769.6M, up 18% reported, 20% organic; US +17%, international +22% reported (+28% organic).
Dexcom Q2 revenue $696.2M (+17% YoY); GAAP EPS $0.12, Non-GAAP EPS $0.17
Revenue $696.2M, +17% reported, +16% organic; U.S. +11%, international +39% reported (+34% organic).
Dexcom authorizes $700M share repurchase program through June 30, 2023
Board committee approved a share repurchase program for up to $700M of outstanding common stock.
DexCom completes 4-for-1 stock split, increases authorized shares to 800M
Effective June 10, 2022, DexCom's common stock split 4-for-1.
On May 9, 2025, Jacob S. Leach was promoted to President and Chief Operating Officer of DexCom, Inc. (the “Company”) effective immediately.
On May 1, 2025, Karen Dahut, a director of DexCom, Inc. (the “Company”), resigned from the Board of Directors (the “Board”) of the Company and all committees thereof effective May 8, 2025.
On March 6, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom”) increased the size of the Board to eleven directors and appointed Renée Galá as a director effective immediately.
Effective on August 24, 2023, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom”) elected Rimma Driscoll to fill a vacancy on the Board and to replace Nicholas Augustinos as a member of the Audit Committee of the Board and the Technology Committee of the Board.
On August 25, 2022, the Board of Directors (the “Board”) of DexCom, Inc. (the “Company”) promoted Jacob S. Leach to Executive Vice President, Chief Operating Officer, effective August 25, 2022.
On July 5, 2022, DexCom, Inc. (“ Dexcom ”) received notice from Chad M. Patterson of his intention to resign as Executive Vice President, Global Marketing of Dexcom effective on July 15, 2022, in order to pursue another employment opportunity.
On September 8, 2021, DexCom, Inc. (“ Dexcom ”) received notice from Quentin Blackford of his intention to resign as Chief Operating Officer of Dexcom effective on September 17, 2021, in order to pursue another employment opportunity.
Max materiality 0.88 · Median 0.70 · Most common event earnings